Alacizumab pegol
Alacizumab pegol is an antineoplastic agent. Chemically, it is a pegylated F(ab')2 fragment of a monoclonal antibody.[1]
| Monoclonal antibody | |
|---|---|
| Type | F(ab')2 fragment |
| Source | Humanized (from mouse) |
| Target | VEGFR2 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
  | |
References
- International Nonproprietary Names for Pharmaceutical Substances (INN), World Health Organization.
Monoclonals for bone, musculoskeletal, circulatory, and neurologic systems | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Bone ("-os-", "-s(o)-") |
| ||||||||
| Musculoskeletal ("-mul-") |
| ||||||||
| Circulatory ("-c(i[r])-") |
| ||||||||
| Neurologic ("-ne(u)(r)-") |
| ||||||||
| Angiogenesis inhibitor ("-anibi-") |
| ||||||||
| Growth factor ("-gr(o)-") |
| ||||||||
| |||||||||
| Angiopoietin |
| ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| CNTF | |||||||||||
| EGF (ErbB) |
| ||||||||||
| FGF |
| ||||||||||
| HGF (c-Met) |
| ||||||||||
| IGF |
| ||||||||||
| LNGF (p75NTR) |
| ||||||||||
| PDGF |
| ||||||||||
| RET (GFL) |
| ||||||||||
| SCF (c-Kit) | |||||||||||
| TGFβ |
| ||||||||||
| Trk |
| ||||||||||
| VEGF |
| ||||||||||
| Others |
| ||||||||||
| |||||||||||
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.